Citations

Clear

3138 citation(s) found for "Smith, AM".

More Predictable Return of Motor Function with Mepivacaine Versus Bupivacaine Spinal Anesthetic in Total Hip and Total Knee Arthroplasty
Wyles, Cody C. , Pagnano, Mark W. , Trousdale, Robert T. , Sierra, Rafael J. , Taunton, Michael J. , Perry, Kevin I. , Larson, Dirk R. , Amundson, Adam W. , Smith, Hugh M. , Duncan, Christopher M. , Abdel, Matthew P , Sierra, Rafael J , Larson, Dirk , Taunton, Michael J , Wyles, Cody C , Abdel, Matthew P.

Mayo Clinic

Journal of Bone and Joint Surgery | August 26, 2020 | Volume: 102 | Issue: 18 | Pages: 1609-1615

10.2106/jbjs.20.00231 | PMID 32960532 Get It

Background: Spinal anesthesia provides several benefits for patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA), but historically comes at the cost of slow and unpredictable return of lower-extremity motor function related to the use of long-acting local anesthetics. In this prospective, double-blinded, randomized clinical trial we sought to determine if an alternative local anesthetic, mepivacaine, would allow more consistent return of motor function compared with low-dose bupivacaine spinal anesthesia during primary THA and TKA. Methods: This trial was conducted at a single academic institution. Prior to trial initiation an internal pilot study determined that 154 patients were required to achieve 80% power. Patients were randomized in a 1:1 fashion with use of advanced computerized stratification based on procedure, age group, sex, and body mass index. Following the surgical procedure, motor function was assessed every 15 minutes in the nonoperative lower extremity according to the Bromage scale and discontinued once Bromage 0 was achieved (spontaneous movement at hip, knee, and ankle). Results: Return of lower-extremity function was more predictable in patients who received mepivacaine than in those who received low-dose bupivacaine. Among patients who received mepivacaine, 1% achieved motor function return beyond 5 hours compared with 11% of patients who received bupivacaine (p = 0.013). The mean time to return of lower-extremity motor function was 26 minutes quicker in patients who received mepivacaine (185 minutes; 95% confidence interval, 174 to 196 minutes) compared with low-dose bupivacaine (210 minutes; 95% confidence interval, 193 to 228 minutes) (p = 0.016). There were no significant differences in safety outcomes including pain scores, time to participation in physical therapy, incidence of orthostatic hypotension, urinary retention, or transient neurologic symptoms in patients receiving mepivacaine compared with low-dose bupivacaine. Conclusions: In patients undergoing primary THA and TKA, spinal anesthesia with mepivacaine allowed more consistent return of lower-extremity motor function compared with low-dose bupivacaine, without a concomitant increase in complications potentially associated with spinal anesthetics. This is particularly of value in an era of short-stay and outpatient surgical procedures. Level of Evidence: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.
The use of vitamin E for prevention of chemotherapy-induced peripheral neuropathy: A phase III double-blind, placebo controlled study—N05C31
Kottschade, Lisa A. , Sloan, Jeff A. , Mazurczak, Miroslaw, Johnson, David B. , Murphy, Brittany L. , Rowland, Kendrith M. , Berg, Alan R., Stella, Philip J., Loprinzi, Charles L. , Murphy, B., Smith, Daniel Arnold

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 9532-9532

10.1200/jco.2009.27.15_suppl.9532 Get It

9532 Background: Chemotherapy induced peripheral neuropathy (CIPN) continues to be a substantial problem for many cancer patients (pts). Pursuant to promising appearing pilot data, the current study evaluated the use of vitamin E for the prevention of CIPN. Methods: A phase III, randomized, double-blind, placebo controlled study was conducted in pts undergoing therapy with neurotoxic chemotherapy, utilizing twice daily dosing of vitamin E (400mg)/placebo. The primary endpoint was the incidence of grade 2+ sensory neuropathy (SN) toxicity (CTCAE v 3.0) in each treatment arm, analyzed by Chi-square testing. Major eligibility criteria included: planned curative intent adjuvant chemotherapy with neurotoxic chemotherapy, ≥ 18 years of age, ECOG PS of ≤2, no existing peripheral neuropathy or coronary artery disease, no prior treatment with neurotoxic chemotherapy, and no concurrent treatment with neuropathic or opioid pain medication. Planned sample size was 100 patients per arm, to provide 80% power to detect a difference in incidence of grade 2+ SN toxicity from 25% in the placebo group to 10% in the vitamin E group. Results: Two-hundred seven pts were enrolled between 12/01/2006 and 12/14/2007. Cytotoxic agents included taxanes (109), cisplatin (8), carboplatin (2), oxaliplatin (50) or combination (20). Eleven pts canceled prior to starting treatment and there were 7 ineligible pts on study. Thus there were 189 evaluable pts included in the current analysis. In this analysis, there was no difference in the incidence of grade 2+ SN between the 2 arms (vitamin E- 34% [95% CI- 25.0–44.8%] placebo- 29% [20.1–39.4%]; P=0.43). There, likewise, were no significant differences between treatment arms for time to onset of neuropathy (P= 0.72), for chemotherapy dose reductions due to neuropathy (P= 0.21) or patient questionnaire reported neuropathy symptoms. The treatment was well tolerated overall. Conclusions: Vitamin E did not appear to reduce the incidence of sensory neuropathy in the studied group of patients receiving neurotoxic chemotherapy but it appeared to be well tolerated. No significant financial relationships to disclose.
Prospective evaluation of patient perceptions and willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials
Smith, Joel, Benjamin, Martin, Yim, Jessica, James, R. L., Ramanathan, Rajesh , Anthony, S. P., Bay, Rihab, Piper, Barbara F., Benjamin, M., Yim, J. H., Ramanathan, R. K., Borad, Mitesh J. , Bay, R. C., Tibes, Raoul

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 6587-6587

10.1200/jco.2009.27.15_suppl.6587 Get It

6587 Background: Increasing numbers of clinical trials include optional or mandatory pharmaco-dynamic and -kinetic assays. Since little is known about patients’ (pts) perceived willingness to undergo specific tests and the number of tests pts would tolerate on a single trial, this study was conducted. Secondary purposes included correlating test number and type with demographics, prior test experience, coverage, and inconvenience. Methods: Exploratory correlative study using a multi-item self-report questionnaire to measure pts willingness (0–10 scale, 0 = not willing, 10 = very willing) to undergo imaging (e.g., MRI, ECHO), invasive (e.g., tumor, skin biopsies [bx]) and less invasive tests (e.g., blood, urine). 61 pts (22 female, 39 male) with advanced malignancies participating in phase I or II trials at one institution were enrolled from June 2008-December 2008. Descriptive and non-parametric statistics were used. Results: Statistically significant (p < 0.01) inverse relationships were found between the number of imaging studies (e.g., CT, ECHO), tests required (e.g., tumor, skin bx, blood draws) and pts reported willingness to undergo these tests. Pts were least willing to undergo tumor bx (median 5.5, interquartile range [IQR] 3.5–10), skin bx (6.8, 3.1–10), and unexpectedly MRIs (8, 4–10) (all p < 0.01). Surprisingly, inconvenience and prior negative experiences for the more invasive tests (e.g., skin bx) did not negatively affect willingness to undergo these tests in the future as opposed to most imaging studies. College-educated were more willing to undergo tests than non-college educated. Few pts were unwilling to undergo tests/procedures at all, if mandatory for enrollment. Conclusions: Results provide improved understanding of pts willingness to undergo trial requirements and suggest that adequate explanation (e.g., MRI) and test rationale may affect willingness to undergo tests. Findings can be used to improve study design and consent procedures to minimize patient discomfort and inconvenience. The overall willingness of advanced stage cancer pts to undergo study specific tests/procedures is high. No significant financial relationships to disclose.
SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study
Hoff, Daniel D. Von , Ramanathan, Ramesh K., Laheru, Dan, Wood, Timothy R. , Korn, Ronald L. , Desai, Neil, Borad, Mitesh J. , Smith, L., Wood, T., Iglesias, José , Hidalgo, Manuel

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 4525-4525

10.1200/jco.2009.27.15_suppl.4525 Get It

4525 Background: Pancreatic cancer cells and surrounding stroma are known to overexpress SPARC (secreted protein acid rich in cysteine), which is associated with poor clinical outcomes. nab-P, an albumin-bound nanoparticle form of paclitaxel increased tumor accumulation of paclitaxel through binding of albumin to SPARC. This disease specific phase 1 study was designed to evaluate the safety and efficacy of G + nab-P and the correlation of response with tumor SPARC and serum CA19–9 levels. Methods: nab-P doses (100–150 mg/m2) + (G) (1000 mg/m2) were given on days 1, 8, and 15 of a 28-day cycle to pts with metastatic pancreatic adenocarcinoma and with no prior chemotherapy for their metastatic disease. Level 3 SPARC staining by immunohistochemistry was considered positive. Results: 63 pts received treatment. The most common grade 3 and 4 adverse event that occurred in >20% of pts was neutropenia. Nine (18%) pts and 4 (8%) pts had a grade 3/4 event, respectively. Neuropathy was also observed. One combination-associated death due to sepsis occurred at the 150 mg/m2 nab-P level. Serial PET scans of 53 pts with outside adjudication to date showed 12 (23%) complete responses, 29 (55%) partial responses (PRs) and 4 (8%) stable disease (SD). By RECIST criteria, of the 49 pts evaluable to date, 1(2%) had CR, 12 (24%) had PR, and 20 (41%) had SD. The median survival was 9 months to date. SPARC data were available for 35 pts, of which 10 (29%) were SPARC+ and 25 (71%) were SPARC-. Of these, 27 pts had evaluable response data. Pts that were SPARC+ (8/27) were more likely to be responders (6/8, 75%) than pts who were SPARC- (5/19, 26%), P = 0.03, Fisher's exact test. Median progression-free survival (PFS) increased from 4.8 months for SPARC- pts (22 pts) to 6.2 months for SPARC+ pts (9 pts); however, these data are still immature. Of 45 pts with elevated CA19–9 at baseline, 42 (93%) had maximum decrease of >40% with a median maximum decrease of 92%. Conclusions: The combination of nab-P and G was generally well tolerated and had substantial enough antitumor activity in patients with pancreatic cancer to warrant a phase III clinical trial. SPARC+ status in these patients was associated with higher response rate and longer PFS. [Table: see text]
Psychometric properties of the self‐efficacy for managing mild cognitive impairment scale
Kurasz, Andrea M. , DeFeis, Brittany , Wit, Liselotte De , Amofa, Priscilla , Chandler, Melanie , Locke, Dona E.C. , De Wit, Liselotte , Smith, Glenn E.

Mayo Clinic

International Journal of Geriatric Psychiatry | August 24, 2020 | Volume: 36 | Issue: 1 | Pages: 174-181

10.1002/gps.5411 | PMID 32830353 Get It

ObjectivesWe adapted a self‐efficacy measure for managing chronic illness to be specific to persons with mild cognitive impairment (pwMCI). The aim of this study was to investigate the psychometric properties of the scale, the self‐efficacy for managing MCI scale, for use in research.MethodsAnalyses involved data from pwMCI enrolled in a behavioral intervention study that completed the measure five times from intervention enrollment to 18‐month post‐intervention. Factor structure, construct validity, internal consistency, and test‐retest reliability were analyzed.ResultsFactor analysis identified two factors, related to self‐efficacy for daily activities and managing MCI, which corresponded with domains from the original chronic illness self‐efficacy scale. Consistent with prior research, construct validity analysis suggested an association between memory‐loss self‐efficacy and psychosocial distress, but not cognitive or functional ability. Further analyses supported the scale's internal and test‐retest reliability.ConclusionsCurrently, no “gold standard” scale of memory‐loss self‐efficacy for pwMCI exists, despite the positive impact self‐efficacy may have on modifiable health behaviors. Overall, results supported the notion that the scale is a valid and reliable measure of memory‐loss self‐efficacy for pwMCI.
Ultradelayed Arterial Thrombosis
Smith, Jesse , Teven, Chad M. , Choudry, Umar , Gottlieb, Lawrence J.

Mayo Clinic

Annals of Plastic Surgery | August 21, 2020 | Volume: 86 | Issue: 2 | Pages: 182-187

10.1097/sap.0000000000002508 | PMID 32826439 Get It

Background and Objectives Delayed arterial thrombus causing loss of a cutaneous free flap at or beyond 6 months is a rare phenomenon. The purpose of this report is to describe 2 cases of arterial compromise requiring medical and surgical intervention at or beyond 6 months after radial forearm free flap (RFFF) phalloplasty and to define the phenomenon of ultradelayed arterial thrombosis. Methods Patient 1 is a 44-year-old transmale who presented with pulselessness, pallor, and hypersensitivity of his neophallus 10 years status post-RFFF phalloplasty using a saphenous vein interposition graft (SVIG) between the superficial femoral artery (SFA) and radial artery (RA). Patient 2 is a 35-year-old transmale who presented with similar complaints 6 months status post-RFFF phalloplasty with the same vascular connections as above. Results Patient 1 was found to have an arterial thrombus distal to the SFA-SVIG anastomosis requiring catheter-directed thrombolysis with tissue plasminogen activator, resulting in partial loss limited to the distal three fourths of the shaft. Patient 2 was also found to have an arterial thrombus distal to the SFA-SVIG anastomosis requiring catheter-directed thrombolysis with tissue plasminogen activator and common femoral artery CFA-RA bypass, resulting in partial loss limited to the neoglans. Conclusions Ultradelayed arterial thrombosis is a rare phenomenon requiring urgent intervention. The exact causes of this phenomenon, whether mechanical or physiological or both, have yet to be fully elucidated but it is hypothesized that the original anastomosis may continue to serve as the critical blood supply to its flap as far as 10 years after surgery.
Update to the ASFA guidelines on the use of therapeutic apheresis in ANCA‐associated vasculitis
Balogun, Rasheed A. , Sanchez, Amber P. , Klingel, Reinhard , Witt, Volker, Aqui, Nicole A., Meyer, Erin , Padmanabhan, Anand , Wu, Yanyun , Zantek, Nicole D. , Connelly‐Smith, Laura , Zantek, Nicole D , Connelly-Smith, Laura , Dunbar, Nancy M , Pham, Huy P. , Schneiderman, Jennifer , Schwartz, Joseph E. , Dunbar, Nancy M.

Mayo Clinic

Journal of Clinical Apheresis | August 8, 2020 | Volume: 35 | Issue: 5 | Pages: 493-499

10.1002/jca.21820 | PMID 32770558 Get It

AbstractSince 1986, the American Society for Apheresis (ASFA) has published practice guidelines on the use of therapeutic apheresis in the Journal of Clinical Apheresis (JCA) Special Issue. Since 2007, updated guidelines have been published every 3 years to reflect current evidence based apheresis practice with the most recent edition (8th) published in 2019. With each edition, the guidelines are reviewed and updated based on any newly published literature since the last review. The PEXIVAS study, an international, randomized controlled trial comparing therapeutic plasma exchange (TPE) vs no TPE and standard vs reduced dose steroid regimen on the primary composite outcome of end stage renal disease or death in patients with ANCA‐associated vasculitis (AAV), was published in February 2020. This study represents the largest study on the role of therapeutic apheresis in AAV published to date and prompted the JCA Special Issue Writing Committee to reassess the current AAV fact sheet for updates based on this newly available evidence. This interim fact sheet summarizes current ASFA recommendations for the evidence‐based use of therapeutic apheresis in AAV and supersedes the recommendations published in the 2019 guidelines.
Fair Play in Minnesota Hockey
Moris, Mae R. , Stuart, Michael J. , Farrell, Kyle , Caputi, Michelle H. , Smith, Aynsley M., Stuart, Michael J , Farrell, Kyle J , Krause, David A.

Mayo Clinic

Safety in Ice Hockey: 6th Volume | August 6, 2020 | Volume: No volume available | Issue: No issue available | Pages: 102-107

10.1520/stp162520190051 Get It

Fair Play (FP) is a behavioral modification program originally created in Quebec, Canada, by Edmund Vaz when injuries, violence, aggressive infractions, and expense drastically decreased ice hockey registration numbers. He found that emphasizing sportsmanship had the potential to reduce dangerous plays. FP awards teams one additional point in the district standings after each game if the following criteria are met: (a) the team remained below the predetermined penalty minute threshold, (b) a coach was not assessed a game misconduct, and (c) none of the spectators were ejected from the arena. In collaboration with the Mayo Clinic, Minnesota Hockey adopted FP successfully in 2004. However, it was only applied to district games, accounting for just 36% of the games in a team's season. FP is currently a loosely recommended model in tournaments and plays no role in nondistrict games. In a study of two youth hockey tournaments, the tournament governed by intensified FP found significantly fewer head hits than the tournament without FP. Junior gold-level tournaments also experienced fewer injuries and concussions when using FP. Despite its established effectiveness, FP is underutilized by Minnesota Hockey. The Mayo Clinic Ice Hockey Research Team (MCIHRT) has therefore determined that FP requires a complete relaunch. The Minnesota Hockey board members, district leaders, and MCIHRT have agreed that increasing visibility and establishing universal application by Minnesota Hockey leadership are the most urgent needs. The MCIHRT action plan addressing shortcomings includes: (a) making a FP announcement before and after games; (b) publishing shortened, universal booklets solely regarding FP; (c) coordinating a distribution of new booklets to coaches, officials, and players/parents; and (d) creating webpages on all district and association sites including the rules of FP and access to the FP standings. Finally, creative ways to increase FP's power to favorably modify behavior will be solicited.
Pressure, Aggression, and Fighting: The Role of Psychosocial Factors in Acute Concussions during Junior A Hockey
Caputi, Michelle H. , Smith, Aynsley M., Erredge, Kristen, Stuart, Michael J. , Stuart, Michael J

Mayo Clinic

Safety in Ice Hockey: 6th Volume | August 6, 2020 | Volume: No volume available | Issue: No issue available | Pages: 82-92

10.1520/stp162520190049 Get It

Hockey is known for speed, skill, hard hits, and fighting. The violence and aggression present in professional hockey contrasts greatly with the skill and finesse of international play. Aggressive behavior across all levels of hockey has devastating long-term consequences resulting from the high prevalence of head trauma. Retired National Hockey League (NHL) players attribute their cognitive difficulties to the repetitive concussive events sustained during their careers. Some retired professional players, such as Daniel Carcillo and Nick Boynton, claim they would trade their name on the Stanley Cup to have known about the long-term consequences of repetitive head trauma. Many retired professional players, such as Ken Dryden, believe the aggressive intent to injure in hockey is completely unnecessary. Junior A hockey is consistently accompanied by a high risk of head trauma. For example, a single Tier III Junior A team experienced thirteen concussions to ten players in one season. Of six players who perceived it “definitely true” that their role on the team was to be an aggressive, forceful, and physical player, four were objectively diagnosed with a concussion during the season. Hypothesized was that intrinsic psychological factors, such as perceived aggression and willingness to fight, and extrinsic factors, such as role modeling by NHL players and feeling pressured by others to fight, contribute to sustaining concussions in hockey. For example, players perceiving themselves as aggressive and physical are at greater risk of concussion than those who see themselves as finesse, skilled players.
Imaging findings of pelvic venous insufficiency in patients with postural orthostatic tachycardia syndrome
Knuttinen, Martha-Gracia, Zurcher, Kenneth S. , Khurana, Neal , Patel, Indravadan , Foxx–Orenstein, Amy E., Harris, Lucinda A. , Lawrence, Andrew, Aguilar, Francisco , Sichlau, Michael J. , Smith, Steven J. , Foxx-Orenstein, Amy, Zurcher, Kenneth , Lawrence, Andrew, Smith, B Holly

Mayo Clinic

Phlebology: The Journal of Venous Disease | August 6, 2020 | Volume: 36 | Issue: 1 | Pages: 32-37

10.1177/0268355520947610 | PMID 32757696 Get It

Objectives Some patients with postural orthostatic tachycardia syndrome (POTS) demonstrate improved dysautonomic symptoms following treatment for pelvic venous insufficiency (PVI). This study assessed the prevalence of significant left common iliac vein (LCIV) compression in POTS patients. Methods Radiologists retrospectively reviewed CT images of pelvic veins for 216 women (191 with POTS and 25 age-comparable controls).Quantitative vascular analysis identified percent-diameter compression of the LCIV by the right common iliac artery. Significant LCIV compression was defined as >50%. Results Significant LCIV compression was found in 69% (131/191) of females with POTS versus 40% (10/25) in controls. The hypothesis that venous compression and presence of POTS are independent was rejected ( p = .005). Conclusions Significant LCIV compression was noted in a majority of female POTS patients, suggesting that incidence of iliac venous obstruction may be higher than the general population. Patients with POTS and symptoms of PVI may benefit from assessment for venous outflow obstruction.